Femiano John MD North Kingstown, RI - 02852

Femiano John MD is categorized under Rehabilitation Center, Outpatient Treatment in North Kingstown, RI and active since 1996.

Femiano John MD was established in 1996, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Rehabilitation Center, Outpatient Treatment business, which does work in the B2C market, and is classified as a Rehabilitation Center, Outpatient Treatment, under code number 6211110 by the NAICS.

If you are seeking more information, feel free to contact John Femiano at the company’s single location by writing to 580 Ten Rod Road, North Kingstown, Rhode Island RI 02852 or by phoning (401) 294-6170. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Femiano John MD
Contact Person: John Femiano
Address: 580 Ten Rod Road, North Kingstown, Rhode Island 02852
Phone Number: (401) 294-6170
Annual Revenue (USD): $100.000 to $499.999
Founded: 1996
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Rehabilitation Center, Outpatient Treatment
SIC Code: 8093
NAICS Code: 6211110
Share This Business:

Femiano John MD was started in 1996 to provide professional Rehabilitation Center, Outpatient Treatment under the SIC code 8093 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact John Femiano for inquiries that concern Femiano John MD by calling the company number (401) 294-6170, as your correspondence is most welcome. Additionally, the physical location of the single location of Femiano John MD can be found at the coordinates 41.57223,-71.48289 as well as the street address 580 Ten Rod Road in North Kingstown, Rhode Island 02852.

For its online presence, you may visit Femiano John MD’s website at and engage with its social media outlets through on Twitter and on Facebook.